News & Views
Merck Announces €59 Million Antibody-Drug Conjugate Manufacturing Expansion
Sep 11 2020
Merck has announced a €59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.
“ADCs have posted incredible growth over the last decade, and regulatory agencies’ approval in recent years demonstrate their promise as a targeted therapy,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck. “With more than 35 years of experience in this space, we have been a frontrunner in the development and manufacturing of biologics, conjugation processes and small molecules. This investment underscores our commitment to working with innovators to bring new treatments to patients quickly and more efficiently.”
Merck’s new 6,500 m2 commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifically designed to handle single-digit nanogram occupational exposure limit materials. The project is an addition to the company’s Madison campus, which was the first commercial ADC facility in North America designed to handle highly active materials. The new building will join Merck’s established campus in St Louis, Missouri, USA, which specialises in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.
More information online
In This Edition Articles - The challenges of Biosample access and what needs to change - Innovative UK exports must gather income - not dust Spotlight Life Sciences - How a Pipettin...
View all digital editions
Sep 21 2021 Lagos, Nigeria
Sep 27 2021 Virtual event
Sep 27 2021 Beijing, China
Sep 28 2021 Glasgow, Scotland
Sep 29 2021 Online event